PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06684028

Enrollment

Registered

2024-11-12

Start date

2023-07-12

Completion date

2025-07-31

Last updated

2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Solid Malignancies

Keywords

FAP, FAPI, PET, cancer

Brief summary

To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.

Detailed description

PET/CT imaging was performed about 1 hour after the patient was injected with the novel tracer 68Ga-FAPI-JNU. SUVmax and SUVmean values of the area of interest were mapped by two diagnostic physicians with more than 5 years of experience after the imaging was completed.

Interventions

DRUG68Ga-FAPI-JNU

Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

1. The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements; 2. Age 18-85 years old, male or female; 3. Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI; 4. ECOG score is 0-3 points;

Exclusion criteria

1. Patients with a history or allergic constitution to any component of the developer, including alcohol; 2. pregnant or lactating women; 3. Patients with mental illness or related history; 4. Patients who cannot or cannot undergo a PET/CT scan;

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of the distribution of 68Ga-FAPI-JNU in tumors, metastases and normal tissues	4 hour	CT and PET scans were performed on the patients injected with 68Ga-FAPI-JNU. After image reconstruction and PET/CT image fusion, the biological distribution of 68Ga-FAPI-JNU in the primary tumor, metastatic tumor and various tissues and organs of the patients was evaluated by radioactive uptake value (standardized uptake value, SUV)

Countries

China

Contacts

Primary Contactchunjing Yu

ycj_wxd1978@163.com15312238622

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026